Show simple item record

dc.contributor.authorIbrahim, Mihad
dc.contributor.authorSabouni, Rana
dc.contributor.authorHusseini, Ghaleb
dc.date.accessioned2021-02-02T08:46:01Z
dc.date.available2021-02-02T08:46:01Z
dc.date.issued2017
dc.identifier.citationMihad Ibrahim, Rana Sabouni and Ghaleb A. Husseini, “Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)”, Current Medicinal Chemistry (2017) 24: 193. https://doi.org/10.2174/0929867323666160926151216en_US
dc.identifier.issn0929-8673
dc.identifier.urihttp://hdl.handle.net/11073/21313
dc.description.abstractCancer is the uncontrolled growth of cells in the body and is considered as one of the major causes of death globally. There are several cytotoxic chemotherapeutic agents used to treat cancer including methotrexate, 5-fluorouracil, cisplatin, tamoxifen, doxorubicin and others. Although billions of dollars have been spent on cancer research to develop these chemotherapies, it still remains a major illness for mankind partly due to the shortcomings of these therapies. These shortcomings include low targeting specificity, severe side effects (due to high doses) and poor pharmacokinetics. To avoid these drawbacks, anti-cancer drug delivery systems have been developed recently using nanocarriers including liposomes, micelles, polyelectrolyte capsules and others. One of the recent class of nanoparticles investigated for chemotherapeutic use are metal organic frameworks (MOFs) which are hybrid polymers that consist of metal ions or clusters and organic ligands. MOFs are used in many applications including gas/vapor separation, gas storage, catalysis, luminescent materials, and biomedical imaging. These structures have additional features that promote their use as drug carriers in the biomedical field. First, they are nontoxic, biodegradable and have the ability to carry high loadings of the anti-neoplastic agent due to their porous nature. Also, they have well-defined crystalline structures that can be characterized by different analytical techniques and their sizes are suitable to control their in vivo drug release.en_US
dc.language.isoen_USen_US
dc.publisherBentham Science Publishersen_US
dc.relation.urihttps://doi.org/10.2174/0929867323666160926151216en_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectMetal-Organic Frameworks (MOFs)en_US
dc.subjectLoadingen_US
dc.subjectReleaseen_US
dc.subjectCytotoxicityen_US
dc.titleAnti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)en_US
dc.typePeer-Revieweden_US
dc.typeArticleen_US
dc.typePostprinten_US
dc.identifier.doi10.2174/0929867323666160926151216


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record